Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBM-BMX in Advanced Solid Tumors
NCT03726294Phase 1Completed
- Sponsor
- NatureWise Biotech & Medicals
- Start
- Oct 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NBM-BMX in solid tumor (advanced stage), sponsored by NatureWise Biotech & Medicals. Primary endpoints: Dose limiting toxicity up to 28 days and Maximum tolerated dose up to 28 days. Started Oct 2018; status: completed.
02
Drugs
NBM-BMX
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03726294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03726294.